Longitudinal changes in serum KL-6 in IPF
Research type
Research Study
Full title
Longitudinal changes in serum KL-6 levels in idiopathic pulmonary fibrosis (LOCK-IPF)
IRAS ID
263851
Contact name
Conal Hayton
Contact email
Sponsor organisation
Manchester University NHS Foundation Trust
Clinicaltrials.gov Identifier
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with a poor prognosis. Effective treatment which slows the progression of IPF has recently become available however, it is costly and at present is limited to patients who meet specific criteria based on their breathing tests. The breathing tests currently available to monitor progression of the disease are not always reliable and do not predict which patients will respond to treatment. More accurate tests to predict disease progression and response to treatment are required.
Krebs von den Lungen-6 (KL-6) is a blood marker associated with IPF. Results from previous studies have shown that levels of KL-6 are higher in patients with IPF compared to people without the disease. The majority of studies using KL-6 in IPF have taken place in Japan and there is limited evidence of how useful it is in a European population. In addition, it is not clear what impact treatment has on KL-6 levels, and whether this could help us to monitor how effective treatment for IPF is.
We plan to perform a study in which we measure KL-6 levels in the blood of patients with a new diagnosis of IPF and perform measurements at 3, 6 and 12 months to look for and changes in the levels of KL-6 in the blood.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
20/NW/0441
Date of REC Opinion
2 Nov 2020
REC opinion
Favourable Opinion